# A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

> **NCT07540442** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 180 (estimated)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** MG-K10 Injection (Humanized Monoclonal Antibody)
- **DRUG:** Placebo for MG-K10

## Key facts

- **NCT ID:** NCT07540442
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2027-01-05
- **Final completion:** 2027-11-09
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540442, "A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07540442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*